Core Viewpoint - Meiz Health (02415) reported a significant increase in both revenue and net profit for the first half of 2025, driven by the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year growth of 13.2% [1] - Net profit amounted to 13.239 million RMB, showing a remarkable year-on-year increase of 5238.3% [1] - Basic earnings per share were 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Industry Trends - The growth in total revenue is attributed to the recovery in the pharmaceutical sector [1] - There is an increasing demand for precision omnichannel marketing solutions, driven by the transformation of domestic pharmaceutical companies [1]

Core Viewpoint - Meiz Health (02415.HK) anticipates a significant increase in shareholder profit for the six months ending June 30, 2025, projecting at least RMB 10 million, compared to a mere RMB 200,000 for the same period in 2024 [1] Group 1: Profit Forecast - The company expects a substantial rise in profit primarily due to the recovery in the pharmaceutical industry [1] - The shift towards evidence-driven marketing models among domestic pharmaceutical companies is driving demand for precise omnichannel marketing solutions [1] - The application of artificial intelligence is enhancing production efficiency across various business segments [1] - The active implementation of environmental, social, and governance (ESG) principles is leading to more effective control of operational costs [1]